
Opinion|Videos|April 3, 2025
Communication of Treatment Options for High-Risk NMIBC
Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you communicate various options for NMIBC with patients and healthcare professionals?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












